Mechanism of Action (MOA)

Mechanism of Action (MOA) describes the specific biochemical, cellular, or physiological processes through which a therapeutic agent produces its intended pharmacological effects, encompassing molecular target identification, binding interactions, downstream signalling consequences, and ultimate effects on disease pathophysiology. Understanding MOA represents fundamental pharmacology informing rational drug design, target selection, biomarker development, patient stratification, combination therapy strategies, and adverse effect prediction throughout pharmaceutical development.

MOA investigation begins during target validation demonstrating that modulating specific proteins or pathways produces desired therapeutic effects, continues through lead optimisation correlating molecular properties with efficacy, and extends into clinical development confirming mechanism relevance in human disease through pharmacodynamic biomarkers and tissue sampling. Regulatory submissions require MOA descriptions supporting indication rationales, dose selection justification, and safety profile interpretation. Different drug classes exhibit characteristic MOA patterns, with enzyme inhibitors blocking catalytic activity, receptor agonists activating signalling pathways, antagonists preventing natural ligand binding, and monoclonal antibodies engaging targets through multiple mechanisms. Gene therapies and cell therapies employ MOAs including replacing defective genes, silencing disease-causing transcripts, or direct cytotoxicity. Resistance mechanisms representing MOA failures through target mutations or pathway bypass inform combination strategies. As systems biology reveals network complexity, MOA understanding becomes increasingly sophisticated supporting more rational therapeutic development.